Lipella Pharmaceuticals

Lipella is developing LP-410, a potential treatment for oral Graft-versus-Host (GvHD) disease. We have been granted Orphan Drug Designation and IND clearance by the FDA for LP-410. $LIPO #mouthcheck #oralcancer #oralcancerawareness #GvHD #raredisease #investors

Today we announce the expansion of Lipella’s Advisory Board to include oncology expertise. https://bit.ly/444pCRP   $LIPO #oncology #advisoryboard #investors #stockstowatch #biotech

We are proud to announce that our abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting. We look forward to sharing more about our recent progress in the treatment of bladder cancer with our new candidate, LP-50. https://bit.ly/3VO7ytb $LIPO #bladdercancer #bladderhealth #asco #investors #stockstowatch

Lipella has been granted a Type C meeting by the FDA to discuss our proposed Phase-2b clinical trial design for LP-10 as a potential treatment for hemorrhagic cystitis. We expect to meet with the FDA on May 21, 2024. https://bit.ly/3xiIMYa $LIPO #raredisease #cystitis #FDA #investors #stockstowatch

April is Oral Cancer Awareness month. Lipella is committed to developing supportive treatments for cancer survivors. $LIPO #mouthcheck #oralcancer #oralcancerawareness #raredisease #investors

Our CEO, Dr. Jonathan Kaufman, shares Lipella’s progress in advancing our clinical pipeline over the past year, and highlights our commitment to addressing significant unmet medical needs, and providing supportive treatments to improve the lives of cancer survivors in a new message: www.lipella.com $LIPO #pipeline #drugdevelopment #raredisease #investors #stockstowatch #stockmarket 

The FDA has approved Lipella’s Investigational New Drug (IND) application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease (GvHD). We expect to begin our study of LP-410 in Q2 2024. https://bit.ly/3T6Ms6v $LIPO #clinicaltrial #IND #GvHD #investors #stockstowatch

Lipella's mission is to develop safe and effective treatments for rare diseases, bringing hope to those who need it the most.